Enzalutamide
Back to searchMolecule Structure
Scientific Name
Enzalutamide
Description of the Drug
Enzalutamide is a second-generation androgen receptor inhibitor used to treat castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08899
http://www.drugbank.ca/drugs/DB08899
Brand Name(s)
Xtandi
Company Owner(s)
Apotex Inc, Actavis Laboratories Fl Inc, Astellas Pharma Us Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Androgen Receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL1871 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL189749 | |
| Human Metabolome Database | HMDB0251831 | |
| DrugBank | DB08899 | |
| PubChem: Thomson Pharma | 22422973 | |
| PubChem | 15951529 | |
| LINCS | LSM-6254 | |
| Nikkaji | J2.922.494C | |
| BindingDB | 50425732 | |
| DrugCentral | 4628 | |
| ChemicalBook | CB62500946 | |
| Guide to Pharmacology | 6812 | |
| rxnorm | ENZALUTAMIDE | XTANDI |
| PubChem: Drugs of the Future | 125299336 | |
| ChEBI | 68534 | |
| ZINC | ZINC000034806477 |
